THSNA 2022 - Chicago, IL

PROGRAM MENU

EDUCATIONAL PROGRAM

PRE-SUMMIT WORKSHOPS

Workshop Schedule

SATELLITE SYMPOSIA

Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2022 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.

View Program Details

Tuesday, August 16th

7:15 - 8:15 AM

ARE HIGHER FACTOR LEVELS A RISING CONSIDERATION WHEN SELECTING A HEMOPHILIA TREATMENT? (SPONSORED BY NOVO NORDISK, INC.)

Chicago Ballroom VI

This program will discuss the clinical relevance of reaching high factor activity levels in patients with hemophilia. An increased risk of bleeding episodes exists with time spent at low factor activity levels, and the World Federation of Hemophilia recognizes the importance of high factor activity levels and maintaining hemostasis in patients with hemophilia. The pharmacokinetic and clinical characteristics of products used to treat patients with hemophilia will also be presented.

Click Here to take the post survey.

NEW CLINICAL DATA FOR PROPHYLAXIS IN VON WILLEBRAND DISEASE AND HEMOPHILIA A (SPONSORED BY OCTAPHARMA AG)

Chicago Ballroom IX-X

Join Jill Johnsen, Robert Sidonio and Craig Kessler for this symposium putting prophylaxis under the spotlight and presenting new clinical data and ongoing investigations for its use in people with von Willebrand disease (VWD) and hemophilia A. The potential for prophylaxis to offer optimal bleed protection in people with VWD will be discussed, supported by new clinical data from a recently completed prospective trial of prophylaxis with a von Willebrand factor/coagulation factor VIII (VWF/FVIII) concentrate. Next generation sequencing (NGS) is a powerful tool whose use to characterize VWF mutations may improve VWD diagnosis and management. In people with severe hemophilia A, prophylaxis is widely accepted as the standard of care, and should be personalized to the patient�s needs. However, the lack of head-to-head studies of different FVIII products makes it challenging to make informed treatment decisions. Insights into the relative effects of different products can be obtained through indirect comparisons using validated statistical methodology. The results of such a comparison of personalized prophylaxis studies in hemophilia A will be presented and discussed. The differential binding capacity for rFVIII concentrates could have implications in platelet biology and new scientific data will be presented.

8:30 - 9:45 AM

PATIENT CENTERED OUTCOMES
Chair/Organizer: Cathy Hayward, Vinai Bhagirath

Sheraton Ballroom IV-V

Introduction Video
.

8:30

Patient Centered Outcomes Research - PCORI Methodology
Mark Skinner. Institute for Policy Advancement Ltd.

8:50

Patient Centered Research - Thrombosis
Elliott Haut. Johns Hopkins Medicine

9:10

Patient Centered Research - Hemostasis
Diane Nugent. CHOC Children's Hospital

9:30

Q&A
.

9:45 - 10:45 AM

POSTERS/EXHIBITS/BREAK

Riverwalk AB

Coffee Break sponsored by Spark Therapeutics, Inc.

10:45 - 11:45 AM

SHORT TALKS - ANTICOAGULATION AND OTHER THERAPIES
Chair/Organizer: Anna Parks, Julie Jaffray

Sheraton Ballroom IV-V

10:45

Adverse Events in Low versus Normal Body Weight Patients Prescribed Apixaban or Rivaroxaban for Atrial Fibrillation.
Deborah DeCamillo¹, Brian Haymart¹, Xiaowen Kong¹, Scott Kaatz², Mona Ali³, Geoffrey Barnes¹, Scott Kaatz⁴. ¹University of Michigan, Ann Arbor, MI, USA.²Henry Ford Health System, Detroit, MI, USA.³Beaumont Health, Royal Oak, MI, USA.⁴Hurley Medical Center, Flint, MI, USA

10:57

Anti-factor Xa-based risk stratification for patients receiving therapeutic enoxaparin is associated with increased risk of recurrent/progressive thrombosis and hemorrhage
Emily C Drake¹, Wallace Bourgeois^{1, 2}, Juliann Duzan¹, Nan Chen^{1, 2}, Nikitha Ramesh¹, Wendy B London^{1, 2}, Riten Kumar^{1, 2}. ¹Boston Children's Hospital, Boston, MA, USA.²Dana Farber Cancer Institute, Boston, MA, USA

11:09

Safety of the Concurrent Use of Four-Factor Prothrombin Complex Concentrate with Andexanet Alfa for Reversal of Factor Xa Inhibitor-Related Bleeding: A Retrospective Case Series Pardis Niami, PharmD, and Todd E. H. Hecht, MD, FACP, SFHM
Pardis Niami, Todd Hecht. Hospital of the University of Pennsylvania, Philadelphia, PA, USA

11:21

Focus group-guided development of a novel bleeding quality of life patient-reported outcome measure for older adults
Anna L. Parks¹, Stacey L. Slager¹, Margaret C. Fang², Mark A. Supiano¹, Patti P. Katz², Daniel M. Witt¹. ¹University of Utah, Salt Lake City, UT, USA.²University of California, San Francisco, San Francisco, CA, USA

11:33

Management of Potential Drug-Drug Interactions with Nirmatrelvir-Ritonavir and Oral Anticoagulants: A Case Series
Aaron S. Wilson¹, Sara R. Vazquez^{1, 2}, Daniel M. Witt^{1, 2}. ¹University of Utah College of Pharmacy Department of Pharmacotherapy, Salt Lake City, UT, USA.²University of Utah Health Community Thrombosis Clinic, Salt Lake City, UT, USA

SHORT TALKS - BLEEDING I
Chair/Organizer: Robert Sidonio, Yasmina Abajas

Sheraton Ballroom I-III

10:45

Impact of anemia on von Willebrand factor and factor VIII in type 1 Von Willebrand disease and mild hemophilia
Maria E. Carter Febres, Cristina Tarango, Matthew Fenchel, Jennifer Pomales, Eric Mullins. Cincinnati Children's Hospital, Cincinnati, OH, USA

10:57

Prophylaxis with Recombinant von Willebrand Factor in Patients with Severe von Willebrand Disease: Phase 3 Trial Results
Frank W.G. Leebeek¹, Flora Peyvandi², Miguel Escobar³, Andreas Tiede⁴, Giancarlo Castaman⁵, Joan Gu⁶, Bjorn Mellgard⁷, Bruce Ewenstein⁷, Gulden Ozen⁷. ¹Erasmus Medical Center, University Medical Center, Rotterdam, Netherlands.²Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca, Milan, Italy.³University of Texas Health Science Center at Houston, Houston, TX, USA.⁴Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.⁵Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.⁶Takeda Development Center Americas, Inc., Lexington, MA, USA.⁷Takeda Development Center Americas, Inc., Cambridge, MA, USA

11:09

Inhibitors of Inorganic Polyphosphate and Nucleic Acids Lead to Decreased Thrombin Generation in Trauma Patients
Taleen A. MacArthur¹, Julie Goswami¹, Sreeparna Vappala ², John Zietlow¹, Stephanie A. Smith³, James H. Morrissey ³, Scott P. Zietlow¹, Grant M. Spears¹, Kent R. Bailey¹, Jing-fei Dong⁴, Rosemary A. Kozar⁵, Jayachandran N. Kizhakkedathu ², Myung S. Park¹. ¹Mayo Clinic, Rochester, MN, USA.²University of British Columbia, Vancouver, BC, USA.³University of Michigan School of Medicine , Ann Arbor, MI, USA.⁴University of Washington School of Medicine, Seattle, WA, USA.⁵Shock Trauma Center, University of Maryland School of Medicine, Baltimore, MD, USA

11:21

Efanesoctocog alfa exhibits von Willebrand factor-independent pharmacokinetics in severe hemophilia A: a post hoc analysis from Phase 1/2a studies
Janice/M. Staber¹, Toshko/J. Lissitchkov², Barbara/A. Konkle³, Amy/D. Shapiro⁴, Doris/V. Quon⁵, Roshni Kulkarni⁶, Melinda Hamilton⁷, Ekta/S. Chhabra⁸, Suresh Katragadda⁸, Arman Altincatal⁹, Annemieke Willemze¹⁰, Jennifer Dumont⁹, Margaret/V. Ragni¹¹. ¹University of Iowa Stead Family Children, Iowa City, IA, USA.²Specialized Hospital for Active Treatment of Hematological Diseases, Department of Chemotherapy, Hemotherapy and Hereditary Blood Diseases at Clinical Hematology Clinic, Sofia Bulgaria.³Washington Center for Bleeding Disorders and the University of Washington, Seattle, WA, USA.⁴Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA.⁵Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA.⁶Michigan State University, East Lansing, MI, USA.⁷Swedish Orphan Biovitrum AB, Stockholm Sweden.⁸Sanofi, Waltham, MA, USA.⁹Sanofi, Cambridge, MA, USA.¹⁰Sanofi, Amsterdam, MA, Netherlands.¹¹Department of Medicine, University of Pittsburgh, and the Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA

SHORT TALKS - LABORATORY ADVANCES
Chair/Organizer: Andrew Goodwin , Cecily Allen

Chicago Ballroom VII

10:45

Factor VIII Levels and International Society on Thrombosis and Hemostasis (ISTH) Disseminated Intravascular Coagulation (DIC) Scores do not Discriminate Coagulopathy of Liver Disease from DIC
Cecily Allen¹, Marina Heskel¹, Ayesha Butt², Alexander Pine², Alfred Lee². ¹Yale School of Medicine, Dept. of Internal Medicine, New Haven, CT, USA.²Yale School of Medicine, Dept. of Hematology, New Haven, CT, USA

10:57

The Heparin Neutralization Step of ELISA Can be Redundant for Heparin-Induced Thrombocytopenia (HIT) Testing
Xiangring He^{1, 2}, Isabella K He³. ¹University Hospitals of Cleveland, Cleveland, OH, USA.²Case Western Reserve University, Cleveland, OH, USA.³Northwestern University, Evanston, IL, USA

11:09

Development of a Modified Bethesda Assay for Determining the Presence of Antidrug Antibodies to Emicizumab
Hande Kizilocak¹, Joshua Brown², Desiree Tan-Castillo², Guy Young^{1, 3}. ¹Children's Hospital Los Angeles, Hemostasis and Thrombosis Center, Los Angeles, CA, USA.²Children, Los Angeles, CA, USA.³University of Southern California, Keck School of Medicine, Los Angeles, CA, USA

11:21

Analysis of genetic mutations and factor VIII assay discrepancy among female carriers of Hemophilia A
Joanna M. Larson^{1, 2}, Katherine E. Addy^{1, 2}, Emma X. Li^{1, 2}, John M. Hancock^{1, 2, 3}, Natalie A. Montanez^{1, 2}, Miguel A. Escobar^{1, 2, 3}. ¹Gulf States Hemophilia and Throbophilia Center, Houston, TX, USA.²Department of Pediatrics, The University of Texas Health Science Center at Houston (UTHealth, Houston), Memorial Hermann, Texas Medical Center, Houston, TX, USA.³Department of Internal Medicine, The University of Texas Health Science Center at Houston (UTHealth, Houston), Memorial Hermann, Texas Medical Center Houston, TX, Houston, TX, USA

12:00 - 1:00 PM

HELP CRACK THE CASE! A HEMOPHILIA A MYSTERY GAME AND AFTERNOON OF DISCUSSION (SPONSORED BY GENENTECH)

Chicago Ballroom IX-X

Genentech invites you to Help Crack the Case!� in a fun-filled interactive mystery game show�at this year's THSNA symposium. You'll hear from real patients and caregivers to find out just who's right for a subcutaneous prophylaxis option, and play along with our expert contestant, Dr. Michael Silvey. Throughout our game show, we�ll explore considerations for identifying potential patients and learn more about the different patient types. You may be surprised at who these �typical� patients turn out to be! Plus, you�ll have an opportunity to have your questions answered in our live Q&A session. We look forward to seeing you there!

LONG-TERM MONITORING OF CLINICAL EFFICACY AND SAFETY PARAMETERS FOR INVESTIGATIONAL HEMOPHILIA GENE THERAPY (SPONSORED BY PFIZER)

Chicago Ballroom VI

This symposium will discuss the importance of patient monitoring both in the short- and long-term, exploring the variables that need to be considered in order to assess clinical efficacy and safety parameters of gene therapy. Presenters of this symposium will explore the practicalities of monitoring these parameters, focusing on coagulation assays and liver investigations, and review the questions that need to be addressed in the future in order to further our understanding of the mechanisms underlying this potential therapeutic approach. Gene therapy for the treatment of hemophilia is investigational. There are no gene therapies currently approved in the US for hemophilia.

1:15 - 2:45 PM

ECMO AND HEMOSTASIS
Chair/Organizer: Nicole Zantek, Leo Brandao

Chicago Ballroom VII

1:15

Anticoagulation Monitoring and Antithrombin III Supplementation in ECMO
William Dager. University of California, Davis Medical Center

1:40

ECMO and Pediatrics
Asavari Kamerkar. Children's Hospital Los Angeles

2:05

Understanding and Utilization of TEG/ROTEM (Thromboelastrography)
Oksana Volod. Cedars Sinai

2:30

Q&A
.

PROCOAGULANT BIOLOGY IN SICKLE CELL DISEASE
Chair/Organizer: Bryce Kerlin, Shannon Meeks

Sheraton Ballroom IV-V

1:15

Endothelial Thrombin - PAR1 Signaling axis in Sickle Cell Disease
Rafal Pawlinski. University of North Carolina at Chapel Hill

1:40

Platelet-mediated contributions to Hgb SS pathobiology
Sruti Shiva. Universitoy of Pittsburgh

2:05

Extracellular Vesicles Disrupt Endothelial Barrier Function in Sickle Cell
Eric Beyer. University of Chicago

2:30

Q&A
.

PSYCHOSOCIAL ASPECTS OF BLEEDING DISORDERS
Chair/Organizer: Lena Volland, Michael Recht

Sheraton Ballroom I-III

INTRODUCTION VIDEO
.

1:15

Impact of Heavy Menstrual Bleeding and Blood Disorders on Quality of Life
Patricia Huguelet. University of Colorado School of Medicine and Children's Hospital Colorado

1:40

Hematologic Issues in Transgender Patients
Joseph Shatzel. Cincinnati Children's Hospital Medical Center

2:05

Depression and suicidality in bleeding disorder community
Maria Iannone. Arizona Hemophilia and Thrombosis Center

2:30

Q&A
.

2:45 - 3:45 PM

POSTERS/EXHIBITS/BREAK

Riverwalk AB

3:45 - 5:15 PM

DIAGNOSIS AND MANAGEMENT OF VON WILLEBRAND DISEASE
Chair/Organizer: Marian Rollins-Raval, Karen Moser

Chicago Ballroom VII

3:45

New Recommendations for diagnosis of VWD from the international guidelines
Robert Sidonio. Aflac Cancer and Blood Disorders and Emory University

4:10

VWD in Women
Maha Othman. Queen's University

4:35

Acquired VWD: Diagnosis and Management
Kristi Smock. University of Utah and ARUP Laboratories

5:00

Q&A
.

INFLAMMATION AND HEMOSTASIS
Chair/Organizer: Bryce Kerlin, Deirdre Nolfi-Donegan

Sheraton Ballroom IV-V

3:45

Fibrinogen and S. Aureus Infection
Matthew Flick. University of North Carolina at Chapel Hill

4:10

Platelet-Neutrophil Crosstalk in Systemic Sclerosis
Roxane Darbousset. Boston children's hospital

4:35

Mechanisms Linking Fibrinogen to Inflammatory Colitis
Joseph Palumbo. Cincinnati Children's Hospital Medical Center and The University of Cincinnati College of Medicine

5:00

Q&A
.

THE CHANGING ROLE OF THE ANTICOAGULATION SERVICE
Chair/Organizer: Vinai Bhagirath, Gary Woods

Sheraton Ballroom I-III

3:45

Are Anticoagulation Clinics the Next Medical Dinosaur?
Elizabeth Renner. Michigan Medicine

4:10

Anticoagulation and Pediatrics: Considerations Across Care Settings
Jennifer Meldau. Childrens National Hospital

4:35

Anticoagulation Models of Care in the Inpatient Setting
Gary Woods. Children's Healthcare of Atlanta and Emory University

5:00

Q&A
.

5:15 - 6:00 PM

POSTERS/EXHIBITS/BREAK

Riverwalk AB

6:00 - 7:15 PM

2022 DINNER SYMPOSIUM: ADVANCING NEW FRONTIERS IN HEMOPHILIA MANAGEMENT (SPONSORED BY BIOMARIN PHARMACEUTICAL INC.)

Chicago Ballroom IX-X

Recognizing the history and reasoning for exploring gene therapy in lifelong conditions like hemophilia will be a focus of this conversation with the experts. During this dinner symposium, attendees will be part of expert discussions on topics relating to liver health in the context of liver-directed gene therapy, follow-up care and surveillance registries in patients with hemophilia, and practical logistics for establishing and maintaining successful gene therapy transfer clinic operations. The four leading experts will provide updates on these cutting-edge, scientific topics followed by an open panel discussion with attendees. We hope that you will join us.

THE FIRST AND ONLY FDA-APPROVED AGENT FOR REVERSAL OF FXA INHIBITOR ACTIVITY IN PATIENTS WITH LIFE-THREATENING OR UNCONTROLLED BLEEDING (SPONSORED BY ASTRAZENECA)

Chicago Ballroom VI

This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.

7:30 - 9:30 PM

VIRTUAL POSTERS (ON-DEMAND ONLY)

Virtual Meeting System